510(k) · Cleared
ClearedSpot Pro (220V), Model 131.099
Data to Oct 25, 2026 (FDA decisions) Oct 12, 2026 (recalls) Sep 30, 2026 (MAUDE) refreshed weekly
Nucletron Corporation · MUJ System, Planning, Radiation Therapy Treatment
Cleared on Oct 24, 2002 as substantially equivalent to K992303 (Nucletron Corp., 2000) after a 66-day review. Its family tree reaches back 2 generations to 1991. 2 later devices descend from it.
- Decided
- Oct 24, 2002
- Review
- 66 days
- Class
- Class II
- Product code
- MUJ
- Recalls
- None
- Predicates
- 1
Its longest line of descent runs back 2 generations to K911612 (1991). 3 ancestors in all. 2 later devices descend from it, 1 citing it directly.
- Root · 2 generations backK911612 Nucletron Planning SystemNucletron-Oldelft Corp. · 1991
- 1 generation backK992303 Sonographic Planning of Oncology Treatments (Spot), Model V.. 1.0Nucletron Corp. · 2000
- This deviceK022741 Spot Pro (220V), Model 131.099Nucletron Corporation · 2002
- Descendant · cites it directly · 1 of its ownK112420 Oncentra Prostate 4.0Nucletron · 2011
- Descendant · 2 generations on · 0 of its ownK170841 BiopSee, Mobile USMedcom GmbH · 2017
Most influential descendants
Showing 2 of 2 · See allView FIG. 1 as a table
Line of descent and top descendants
| Generation | Number | Device | Applicant | Decided | Recalls |
|---|---|---|---|---|---|
| −2 | K911612 | Nucletron Planning System | Nucletron-Oldelft Corp. | 1991 | — |
| −1 | K992303 | Sonographic Planning of Oncology Treatments (Spot), Model V.. 1.0 | Nucletron Corp. | 2000 | — |
| 0 (this device) | K022741 | Spot Pro (220V), Model 131.099 | Nucletron Corporation | 2002 | — |
| +1 | K112420 | Oncentra Prostate 4.0 | Nucletron | 2011 | — |
| +2 | K170841 | BiopSee, Mobile US | Medcom GmbH | 2017 | — |
Other ancestors by year cleared
| Year cleared | Devices | With a Class I recall |
|---|---|---|
| 1996 | 1 | 0 |
Descendants by year cleared
| Year cleared | Devices | With a Class I recall |
|---|---|---|
| 2011 | 1 | 0 |
| 2017 | 1 | 0 |
Sources: FDA 510(k) database (decision fields), the FDA summary (predicates and indications), FDA recall and enforcement reports, and MAUDE; processed by 510(k) Report. Verify on FDA.gov · Methodology and accuracy.
Planning a device in MUJ? A 510(k) Report weighs predicate choices, recall history and review times for a new device like this one.
Top candidate predicates for a new MUJ device
- #1 K232799 syngo.via RT Image Suitescore 18.6 · 19 generations · no Class I recall
- #2 Held for the reportin the report
- #3 Held for the reportin the report
What was it cleared against? (1)
Devices the submitter claimed this one is substantially equivalent to (*), and reference devices cited for a specific test or feature (†), as written in the FDA summary.
| Type | Number | Device | Decided |
|---|---|---|---|
| * | K992303 | Sonographic Planning of Oncology Treatments (Spot), Model V.. 1.0Summary page 2…and dose distribution for the specified loading. From this the information the patient can be treated with radioactive sources. Modifications to SPOT previously cleared K992303, have been made to add functionality for: 0 Post Planning functionality 0 Auto activation dwell positions 0 Auto contouring 0 Usa… | 2000 |
| † | K983343 | Plato Brachytheraphy, Model V. 14.0 | 1999 |
| † | K964206 | Nucletron Plato External Beam Planning RTS V2 and RTS 3D V2 | 1997 |
What descends from it? (2)
1 later device cites it directly; ranked here by how many devices descend from each in turn.
| Number | Device | Decided | Descendants |
|---|---|---|---|
| K112420 | Oncentra Prostate 4.0 | 2011 | 1 |
Has anything in its family been recalled? (0 Class I)
No FDA recall names this device.
No ancestor or descendant has a Class I recall.
What does this lineage say?
- The line of descent spans 11 years and passes through 3 companies; a new generation was cleared every 8.8 years on median.
- None of the 3 ancestors has a recall.
- Of its descendants, K112420 (Nucletron, 2011) has gone furthest, with 1 descendant of its own.
- 1 other device also cites its predicate K992303.
How does its category compare?
All MUJ devicesMUJ System, Planning, Radiation Therapy Treatment: FDA decisions, review times, recalls and adverse event reports over 20 years.
FDA decisions per year · MUJ
10in 2025
2026 to Oct 25, outlined.
Median 510(k) review, days · MUJ
186in 2025
Receipt to decision; years with fewer than 3 clearances left blank.
Recalls per year · MUJ
2in 2023
Class I (0 since 2007) Class II/III not classified
Adverse event reports per year · MUJ
21in 2025
MAUDE reports naming product code MUJ, not matched to any one device; reports are not rates.
View these four charts as a table
| Year | Decisions | Median 510(k) review, days | Recalls (Class I) | MAUDE reports |
|---|---|---|---|---|
| 2007 | 4 | 67 | 4 | 24 |
| 2008 | 9 | 63 | 10 | 51 |
| 2009 | 16 | 84 | 11 | 24 |
| 2010 | 11 | 56 | 23 | 78 |
| 2011 | 9 | 103 | 17 | 73 |
| 2012 | 8 | 59 | 4 | 39 |
| 2013 | 5 | 64 | 6 | 33 |
| 2014 | 9 | 108 | 2 | 35 |
| 2015 | 13 | 78 | 7 | 30 |
| 2016 | 5 | 80 | 13 | 27 |
| 2017 | 7 | 30 | 4 | 16 |
| 2018 | 7 | 53 | 3 | 25 |
| 2019 | 9 | 56 | 4 | 25 |
| 2020 | 9 | 104 | 2 | 26 |
| 2021 | 11 | 87 | 4 | 15 |
| 2022 | 8 | 168 | 3 | 22 |
| 2023 | 10 | 140 | 2 | 76 |
| 2024 | 9 | 122 | 0 | 9 |
| 2025 | 10 | 186 | 0 | 21 |
| 2026 | 9 | 233 | 2 | — |
What is it indicated for?
SPOT PRO is a software application for Brachytherapy Treatment Planning, for the treatment of cancer, i.e. intercavitary, interstitial, intraluminal, involving radioactive sources.
Indications for use as stated in the FDA summary.
https://510kreport.com/device/K022741 · printed Nov 5, 2026
Cite this page
510(k) Report. “K022741: Spot Pro (220V), Model 131.099.” Lineage record from FDA 510(k) data and the FDA summary. Updated Nov 3, 2026. Accessed Nov 5, 2026. https://510kreport.com/device/K022741
Report an extraction error
Are you the manufacturer?
Record history
- FDA decision record loaded May 2, 2026
- Summary read Oct 13, 2026 (extraction version 9eaa42aa01ed)
- Lineage and recalls computed Nov 3, 2026
- Page last updated Nov 3, 2026